Advice

in the absence of a submission from the holder of the marketing authorisation:

rituxumab (MabThera®) is not recommended for use within NHSScotland.

Indication under review: in combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
The holder of the marketing authorisation has not made a submission to SMC regarding this product as maintenance treatment. As a result we cannot recommend its use within NHSScotland.

SMC has previously accepted rituximab for restricted use in combination with glucocorticoids, for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA) (SMC 894/13). This advice remains valid.

Download detailed advice360KB (PDF)

Download

Medicine details

Medicine name:
rituxumab (MabThera)
SMC ID:
SMC2165
Indication:
In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
11 March 2019